ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

Mon, 06 Jul 2026 14:00:00 -0400

Article L233-8-II of the French Commercial Code

Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)

TOULOUSE, France--(BUSINESS WIRE)-- Regulatory News:

ABIONYX Pharma (Paris:ABNX):

Market: Euronext Paris, Compartment C
ISIN code: FR0012616852

Date

Number of shares outstanding

Total voting rights

Total gross (1)

Total net (2)

Article L233-8-II of the French Commercial Code

Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)

TOULOUSE, France--(BUSINESS WIRE)-- Regulatory News:

ABIONYX Pharma (Paris:ABNX):

Market: Euronext Paris, Compartment C
ISIN code: FR0012616852

Date

Number of shares outstanding

Total voting rights

Total gross (1)

Total net (2)

Article L233-8-II of the French Commercial Code

Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)

TOULOUSE, France--(BUSINESS WIRE)-- Regulatory News:

ABIONYX Pharma (Paris:ABNX):

Market: Euronext Paris, Compartment C
ISIN code: FR0012616852

Date

Number of shares outstanding

Total voting rights

Total gross (1)

Total net (2)

Article L233-8-II of the French Commercial Code

Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)

TOULOUSE, France--(BUSINESS WIRE)-- Regulatory News:

ABIONYX Pharma (Paris:ABNX):

Market: Euronext Paris, Compartment C
ISIN code: FR0012616852

Date

Number of shares outstanding

Total voting rights

Total gross (1)

Total net (2)

Article L233-8-II of the French Commercial Code

Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)

TOULOUSE, France--(BUSINESS WIRE)-- Regulatory News:

ABIONYX Pharma (Paris:ABNX):

Market: Euronext Paris, Compartment C
ISIN code: FR0012616852

Date

Number of shares outstanding

Total voting rights

Total gross (1)

Total net (2)

Article L233-8-II of the French Commercial Code

Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)

TOULOUSE, France--(BUSINESS WIRE)-- Regulatory News:

ABIONYX Pharma (Paris:ABNX):

Market: Euronext Paris, Compartment C
ISIN code: FR0012616852

Date

Number of shares outstanding

Total voting rights

Total gross (1)

Total net (2)

Article L233-8-II of the French Commercial Code

Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)

TOULOUSE, France--(BUSINESS WIRE)-- Regulatory News:

ABIONYX Pharma (Paris:ABNX):

Market: Euronext Paris, Compartment C
ISIN code: FR0012616852

Date

Number of shares outstanding

Total voting rights

Total gross (1)

Total net (2)

Article L233-8-II of the French Commercial Code

Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)

TOULOUSE, France--(BUSINESS WIRE)-- Regulatory News:

ABIONYX Pharma (Paris:ABNX):

Market: Euronext Paris, Compartment C
ISIN code: FR0012616852

Date

Number of shares outstanding

Total voting rights

Total gross (1)

Total net (2)

Number of shares: 118,866 shares

Cash balance: €96,894.38

During the first half of 2026, a total of:

PURCHASES

282,460 shares

€933,897.51

ABIONYX Pharma: Half-Year Review of the Liquidity Agreement Entered into with TP ICAP (Europe) SA

Mon, 06 Jul 2026 13:14:00 -0400

TOULOUSE, France--(BUSINESS WIRE)-- Regulatory News:

Under the liquidity agreement covering the shares of ABIONYX Pharma (FR0012616852 – ABNX FP) entrusted to TP ICAP (Europe), the following assets were held in the liquidity account as of June 30, 2026:

Number of shares: 118,866 shares
Cash balance: €96,894.38

During the first half of 2026, a total of:

PURCHASES

282,460 shares

€933,897.51

ABIONYX Pharma: Half-Year Review of the Liquidity Agreement Entered into with TP ICAP (Europe) SA

Mon, 06 Jul 2026 13:14:00 -0400

TOULOUSE, France--(BUSINESS WIRE)-- Regulatory News:

Number of shares: 118,866 shares
Cash balance: €96,894.38

During the first half of 2026, a total of:

PURCHASES

282,460 shares

€933,897.51

ABIONYX Pharma: Half-Year Review of the Liquidity Agreement Entered into with TP ICAP (Europe) SA

Mon, 06 Jul 2026 13:14:00 -0400

TOULOUSE, France--(BUSINESS WIRE)-- Regulatory News:

Number of shares: 118,866 shares
Cash balance: €96,894.38

During the first half of 2026, a total of:

PURCHASES

282,460 shares

€933,897.51

ABIONYX Pharma: Half-Year Review of the Liquidity Agreement Entered into with TP ICAP (Europe) SA

Mon, 06 Jul 2026 13:14:00 -0400

TOULOUSE, France--(BUSINESS WIRE)-- Regulatory News:

Number of shares: 118,866 shares
Cash balance: €96,894.38

During the first half of 2026, a total of:

PURCHASES

282,460 shares

€933,897.51

ABIONYX Pharma: Half-Year Review of the Liquidity Agreement Entered into with TP ICAP (Europe) SA

Mon, 06 Jul 2026 13:14:00 -0400

TOULOUSE, France--(BUSINESS WIRE)-- Regulatory News:

Number of shares: 118,866 shares
Cash balance: €96,894.38

During the first half of 2026, a total of:

PURCHASES

282,460 shares

€933,897.51

ABIONYX Pharma: Half-Year Review of the Liquidity Agreement Entered into with TP ICAP (Europe) SA

Mon, 06 Jul 2026 13:14:00 -0400

TOULOUSE, France--(BUSINESS WIRE)-- Regulatory News:

Number of shares: 118,866 shares
Cash balance: €96,894.38

During the first half of 2026, a total of:

PURCHASES

282,460 shares

€933,897.51

ABIONYX Pharma: Half-Year Review of the Liquidity Agreement Entered into with TP ICAP (Europe) SA

Mon, 06 Jul 2026 13:14:00 -0400

TOULOUSE, France--(BUSINESS WIRE)-- Regulatory News:

Number of shares: 118,866 shares
Cash balance: €96,894.38

During the first half of 2026, a total of:

PURCHASES

282,460 shares

€933,897.51

ABIONYX Pharma is Scaling up Its Operations After Securing the Resources Needed to Achieve Its Goals and Is Embarking on a New Cycle of Value Creation in the Treatment of Severe Inflammation and Sepsi

Tue, 30 Jun 2026 13:08:00 -0400

All resolutions submitted for a vote at today’s Combined General Meeting were approved
Launch of the largest pivotal clinical trial for CER-001 in sepsis, the 3rd cause of death worldwide
Progress in regulatory and manufacturing phases toward approval of CER-001 for LCAT deficiency
Financial visibility through the end of 2028 following the raising of up to €33 million
Focus on leveraging and optimizing a unique scientific apoA-I platform

TOULOUSE, France & FULLERTON, Calif.--(BUSINESS WIRE)-- Regulatory News:

ABIONYX Pharma (FR0012616852 – ABNX – eligible for the PEA PME program), a next-generation biopharmaceutical company developing innovative therapies for sepsis and critical care based on

ABIONYX Pharma is Scaling up Its Operations After Securing the Resources Needed to Achieve Its Goals and Is Embarking on a New Cycle of Value Creation in the Treatment of Severe Inflammation and Sepsi

Tue, 30 Jun 2026 13:08:00 -0400

All resolutions submitted for a vote at today’s Combined General Meeting were approved
Launch of the largest pivotal clinical trial for CER-001 in sepsis, the 3rd cause of death worldwide
Progress in regulatory and manufacturing phases toward approval of CER-001 for LCAT deficiency
Financial visibility through the end of 2028 following the raising of up to €33 million
Focus on leveraging and optimizing a unique scientific apoA-I platform

TOULOUSE, France & FULLERTON, Calif.--(BUSINESS WIRE)-- Regulatory News:

ABIONYX Pharma (FR0012616852 – ABNX – eligible for the PEA PME program), a next-generation biopharmaceutical company developing innovative therapies for sepsis and critical care based on

ABIONYX Pharma is Scaling up Its Operations After Securing the Resources Needed to Achieve Its Goals and Is Embarking on a New Cycle of Value Creation in the Treatment of Severe Inflammation and Sepsi

Tue, 30 Jun 2026 13:08:00 -0400

All resolutions submitted for a vote at today’s Combined General Meeting were approved
Launch of the largest pivotal clinical trial for CER-001 in sepsis, the 3rd cause of death worldwide
Progress in regulatory and manufacturing phases toward approval of CER-001 for LCAT deficiency
Financial visibility through the end of 2028 following the raising of up to €33 million
Focus on leveraging and optimizing a unique scientific apoA-I platform

TOULOUSE, France & FULLERTON, Calif.--(BUSINESS WIRE)-- Regulatory News:

ABIONYX Pharma (FR0012616852 – ABNX – eligible for the PEA PME program), a next-generation biopharmaceutical company developing innovative therapies for sepsis and critical care based on

ABIONYX Pharma is Scaling up Its Operations After Securing the Resources Needed to Achieve Its Goals and Is Embarking on a New Cycle of Value Creation in the Treatment of Severe Inflammation and Sepsi

Tue, 30 Jun 2026 13:08:00 -0400

All resolutions submitted for a vote at today’s Combined General Meeting were approved
Launch of the largest pivotal clinical trial for CER-001 in sepsis, the 3rd cause of death worldwide
Progress in regulatory and manufacturing phases toward approval of CER-001 for LCAT deficiency
Financial visibility through the end of 2028 following the raising of up to €33 million
Focus on leveraging and optimizing a unique scientific apoA-I platform

TOULOUSE, France & FULLERTON, Calif.--(BUSINESS WIRE)-- Regulatory News:

ABIONYX Pharma (FR0012616852 – ABNX – eligible for the PEA PME program), a next-generation biopharmaceutical company developing innovative therapies for sepsis and critical care based on

ABIONYX Pharma Announces the Success of its Financing for a Total Maximum Amount of EUR 33 M

Thu, 18 Jun 2026 01:30:00 -0400

Capital increase fully subscribed for a total amount of EUR 18.7 M through the issuance of 7,056,416 New Shares at a subscription price of EUR 2.65 per share
Drawdown of the First Tranche of the Bonds Financing for an amount of EUR 10 M out of a total amount of EUR 14 M and issuance of the Warrants to Fenja Capital
Subscription by existing shareholders for approximately 40% of the capital increase through the exercise of their subscription rights and fulfillment of their guarantee commitments
Extension of the Company’s cash runway into Q4 2028 after drawdown of the second tranche of the

ABIONYX Pharma Announces the Success of its Financing for a Total Maximum Amount of EUR 33 M

Thu, 18 Jun 2026 01:30:00 -0400

Capital increase fully subscribed for a total amount of EUR 18.7 M through the issuance of 7,056,416 New Shares at a subscription price of EUR 2.65 per share

Drawdown of the First Tranche of the Bonds Financing for an amount of EUR 10 M out of a total amount of EUR 14 M and issuance of the Warrants to Fenja Capital

Subscription by existing shareholders for approximately 40% of the capital increase through the exercise of their subscription rights and fulfillment of their guarantee commitments

Extension of the Company’s cash runway into Q4 2028 after drawdown of the second tranche of the

ABIONYX Pharma Announces the Success of its Financing for a Total Maximum Amount of EUR 33 M

Thu, 18 Jun 2026 01:30:00 -0400

Capital increase fully subscribed for a total amount of EUR 18.7 M through the issuance of 7,056,416 New Shares at a subscription price of EUR 2.65 per share

Drawdown of the First Tranche of the Bonds Financing for an amount of EUR 10 M out of a total amount of EUR 14 M and issuance of the Warrants to Fenja Capital

Subscription by existing shareholders for approximately 40% of the capital increase through the exercise of their subscription rights and fulfillment of their guarantee commitments

Extension of the Company’s cash runway into Q4 2028 after drawdown of the second tranche of the

ABIONYX Pharma Announces the Success of its Financing for a Total Maximum Amount of EUR 33 M

Thu, 18 Jun 2026 01:30:00 -0400

Capital increase fully subscribed for a total amount of EUR 18.7 M through the issuance of 7,056,416 New Shares at a subscription price of EUR 2.65 per share

Drawdown of the First Tranche of the Bonds Financing for an amount of EUR 10 M out of a total amount of EUR 14 M and issuance of the Warrants to Fenja Capital

Subscription by existing shareholders for approximately 40% of the capital increase through the exercise of their subscription rights and fulfillment of their guarantee commitments

Extension of the Company’s cash runway into Q4 2028 after drawdown of the second tranche of the

ABIONYX Pharma Announces the Success of its Financing for a Total Maximum Amount of EUR 33 M

Thu, 18 Jun 2026 01:30:00 -0400

Capital increase fully subscribed for a total amount of EUR 18.7 M through the issuance of 7,056,416 New Shares at a subscription price of EUR 2.65 per share

Drawdown of the First Tranche of the Bonds Financing for an amount of EUR 10 M out of a total amount of EUR 14 M and issuance of the Warrants to Fenja Capital

Subscription by existing shareholders for approximately 40% of the capital increase through the exercise of their subscription rights and fulfillment of their guarantee commitments

Extension of the Company’s cash runway into Q4 2028 after drawdown of the second tranche of the

StreetInsider.com News Articles

ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital

ABIONYX Pharma: Half-Year Review of the Liquidity Agreement Entered into with TP ICAP (Europe) SA

ABIONYX Pharma: Half-Year Review of the Liquidity Agreement Entered into with TP ICAP (Europe) SA

ABIONYX Pharma: Half-Year Review of the Liquidity Agreement Entered into with TP ICAP (Europe) SA

ABIONYX Pharma: Half-Year Review of the Liquidity Agreement Entered into with TP ICAP (Europe) SA

ABIONYX Pharma: Half-Year Review of the Liquidity Agreement Entered into with TP ICAP (Europe) SA

ABIONYX Pharma: Half-Year Review of the Liquidity Agreement Entered into with TP ICAP (Europe) SA

ABIONYX Pharma: Half-Year Review of the Liquidity Agreement Entered into with TP ICAP (Europe) SA

ABIONYX Pharma is Scaling up Its Operations After Securing the Resources Needed to Achieve Its Goals and Is Embarking on a New Cycle of Value Creation in the Treatment of Severe Inflammation and Sepsi

ABIONYX Pharma is Scaling up Its Operations After Securing the Resources Needed to Achieve Its Goals and Is Embarking on a New Cycle of Value Creation in the Treatment of Severe Inflammation and Sepsi

ABIONYX Pharma is Scaling up Its Operations After Securing the Resources Needed to Achieve Its Goals and Is Embarking on a New Cycle of Value Creation in the Treatment of Severe Inflammation and Sepsi

ABIONYX Pharma is Scaling up Its Operations After Securing the Resources Needed to Achieve Its Goals and Is Embarking on a New Cycle of Value Creation in the Treatment of Severe Inflammation and Sepsi

ABIONYX Pharma Announces the Success of its Financing for a Total Maximum Amount of EUR 33 M

ABIONYX Pharma Announces the Success of its Financing for a Total Maximum Amount of EUR 33 M

ABIONYX Pharma Announces the Success of its Financing for a Total Maximum Amount of EUR 33 M

ABIONYX Pharma Announces the Success of its Financing for a Total Maximum Amount of EUR 33 M

ABIONYX Pharma Announces the Success of its Financing for a Total Maximum Amount of EUR 33 M